Search research articles
Contact Us
Filters
Showing results (61-70 of 105) with videos related to
Page
of 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 22, 2009
A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia
Alexander E Perl, Margaret T Kasner, Donald E Tsai, et al.
Transplantation and Cellular Therapy
|
November 6, 2022
Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies
Matthew P Connor, Alison W Loren, Elizabeth O Hexner, et al.
Blood
|
August 30, 2014
Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802
Javier Bolaños-Meade, Brent R Logan, Amin M Alousi, et al.
Blood Advances
|
January 31, 2025
Evolving racial/ethnic disparities in AML survival in the novel therapy era
Xin Wang, Phyllis A Gimotty, Andrew H Matthews, et al.
Journal of Hematology & Oncology
|
February 24, 2017
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Blood Advances
|
May 4, 2022
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia
Andrew H Matthews, Alexander E Perl, Selina M Luger, et al.
JCI Insight
|
May 10, 2022
A phase I trial of cyclosporine for hospitalized patients with COVID-19
Emily A Blumberg, Julia Han Noll, Pablo Tebas, et al.
Cancer Discovery
|
April 3, 2023
Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell-Intrinsic Dysfunction
In-Young Jung, Robert L Bartoszek, Andrew J Rech, et al.
Haematologica
|
January 25, 2015
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Nature Medicine
|
December 7, 2021
Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial
Jason Gotlib, Andreas Reiter, Deepti H Radia, et al.
Page
of 11
Search research articles
Search
Showing results (61-70 of 105) with videos related to
Sort By:
Page
of 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 22, 2009
A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia
Alexander E Perl, Margaret T Kasner, Donald E Tsai, et al.
Transplantation and Cellular Therapy
|
November 6, 2022
Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies
Matthew P Connor, Alison W Loren, Elizabeth O Hexner, et al.
Blood
|
August 30, 2014
Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802
Javier Bolaños-Meade, Brent R Logan, Amin M Alousi, et al.
Blood Advances
|
January 31, 2025
Evolving racial/ethnic disparities in AML survival in the novel therapy era
Xin Wang, Phyllis A Gimotty, Andrew H Matthews, et al.
Journal of Hematology & Oncology
|
February 24, 2017
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Blood Advances
|
May 4, 2022
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia
Andrew H Matthews, Alexander E Perl, Selina M Luger, et al.
JCI Insight
|
May 10, 2022
A phase I trial of cyclosporine for hospitalized patients with COVID-19
Emily A Blumberg, Julia Han Noll, Pablo Tebas, et al.
Cancer Discovery
|
April 3, 2023
Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell-Intrinsic Dysfunction
In-Young Jung, Robert L Bartoszek, Andrew J Rech, et al.
Haematologica
|
January 25, 2015
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Nature Medicine
|
December 7, 2021
Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial
Jason Gotlib, Andreas Reiter, Deepti H Radia, et al.
Page
of 11